Table 1 Baseline characteristics of the participants stratified by type of boost vaccination
Characteristic | All (n = 85) | Heterologous boost with Sf9 cells vaccine (n = 44) | Homologous boost with CoronaVac vaccine (n = 41) | p value |
|---|---|---|---|---|
Age, years | 0.363 | |||
Median (Min, Max) | 49 (23, 70) | 49 (25, 67) | 46 (23, 70) | |
Age subgroup, n (%) | 0.039 | |||
18–59 years | 67 (78.80) | 35 (79.50) | 32 (78.05) | |
≥60 years | 18 (21.20) | 9 (20.40) | 9 (21.95) | |
Sex, n (%) | 0.881 | |||
Male | 40 (47.10) | 22 (50.0) | 18 (43.90) | |
Female | 45 (52.90) | 22 (50.0) | 23 (56.10) | |
Height, cm | 0.838 | |||
Median (Min,Max) | 164.0 (136.5, 180.0) | 164.0 (136.5, 180.0) | 164.0 (149.0, 179.5) | |
Weight, kg | 0.996 | |||
Median (Min Max) | 61.4 (42.0, 98.5) | 61.8 (42.0, 82.0) | 61.1 (48.5, 98.5) | |
BMI, kg/m2 | 0.883 | |||
Median (Min, Max) | 23.7 (17.5, 33.3) | 23.7 (17.5, 33.0) | 23.7 (18.3, 33.3) | |
Preexisting co-morbidities*, n (%) | 0.043 | |||
Yes | 6 (7.06) | 1 (2.27) | 5 (12.19) | |
No | 79 (92.94) | 43 (97.73) | 36 (87.80) | |
Time between third vaccination and the fourth booster doses in the present study, days | 0.178 | |||
Mean (±SD) | 286.09 ( ± 44.57) | 277.84 ( ± 48.19) | 294.95( ± 38.97) | |
Median (Min, Max) | 283 (220, 351) | 273 (220, 351) | 313 (222, 336) | |
